It's the GeneMedi's summary page for Target/Biomarker Introduction of CD3E. The page also collects GeneMedi's different modalities and formats products for CD3E in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CD3E target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
The protein encoded by this gene is the CD3-epsilon polypeptide, which together with CD3-gamma, -delta and -zeta, and the T-cell receptor alpha/beta and gamma/delta heterodimers, forms the T-cell receptor-CD3 complex. This complex plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. The genes encoding the epsilon, gamma and delta polypeptides are located in the same cluster on chromosome 11. The epsilon polypeptide plays an essential role in T-cell development. Defects in this gene cause immunodeficiency. This gene has also been linked to a susceptibility to type I diabetes in women. [provided by RefSeq, Jul 2008]
Target ID | GM-T87075 |
Target Name | CD3E |
Gene ID | 916,12501,315609,699467,442981,493936,281054,100629532 |
Gene Symbol and Synonyms | CD3,CD3E,CD3epsilon,IMD18,T3E,TCRE |
Uniprot Accession | P07766,P27597,Q5R1Q1,Q28073 |
Uniprot Entry Name | CD3E_HUMAN,CD3E_FELCA,CD3E_CANLF,CD3E_BOVIN |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, Immuno-oncology Target, INN Index |
Disease | N/A |
Gene Ensembl | ENSG00000198851 |
Target Classification | Checkpoint-Immuno Oncology |
Pre-made CD3E-specific INN-index biosimilar (antibody&conjugates)
Anti-CD3E therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Cat No. | Products Name (INN Index) | INN Name | Previous Name | Target | Format | Detail |
GMP-Bios-ab-356 | Pre-Made Mosunetuzumab biosimilar, Bispecific mAb, Anti-CD3E;MS4A1/CD20 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody | Mosunetuzumab | | CD3E;MS4A1/CD20 | Bispecific mAb | Detail |
GMP-Bios-INN-790 | Pre-Made Dafsolimab Setaritox Biosimilar, Whole Mab Adc, Anti-Cd3E Antibody: Anti-CD3epsilon/IMD18/T3E/TCRE therapeutic antibody Drug Conjugate | dafsolimab setaritox | | CD3E | Whole mAb ADC | Detail |
GMP-Bios-ab-546 | Pre-Made Talquetamab biosimilar, Bispecific mAb, Anti-GPRC5D;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody | Talquetamab | | GPRC5D;CD3E | Bispecific mAb | Detail |
GMP-Bios-ab-622 | Pre-Made Visilizumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody | Visilizumab | | CD3E | Whole mAb | Detail |
GMP-Bios-ab-386 | Pre-Made Obrindatamab biosimilar, Bispecific scFv with Domain Crossover, Anti-CD276;CD3E Antibody: Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2;T3E/TCRE/IMD18 therapeutic antibody | Obrindatamab | | CD276;CD3E | Bispecific scFv with Domain Crossover | Detail |
GMP-Bios-ab-104 | Pre-Made Cibisatamab biosimilar, Bispecific mAb with Domain Crossover: Anti-CEACAM5;CD3E therapeutic antibody | Cibisatamab | | CEACAM5;CD3E | Bispecific mAb with Domain Crossover | Detail |
GMP-Bios-ab-391 | Pre-Made Odronextamab biosimilar, Bispecific mAb, Anti-MS4A1/CD20;CD3E Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7;T3E/TCRE/IMD18 therapeutic antibody | Odronextamab | | MS4A1/CD20;CD3E | Bispecific mAb | Detail |
GMP-Bios-ab-500 | Pre-Made Runimotamab biosimilar, Bispecific mAb, Anti-ERBB2/HER2;CD3E Antibody: Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;T3E/TCRE/IMD18 therapeutic antibody | Runimotamab | | ERBB2/HER2;CD3E | Bispecific mAb | Detail |
GMP-Bios-ab-248 | Pre-Made Glofitamab biosimilar, Bispecific mAb with Domain Crossover, Anti-CD3E;MS4A1/CD20 antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7therapeutic antibody | Glofitamab | | CD3E;MS4A1/CD20 | Bispecific mAb with Domain Crossover | Detail |
GMP-Bios-ab-705 | Pre-Made Ubamatamab biosimilar, Whole mAb, Anti-MUC16;CD3E Antibody: Anti-CA125;T3E/TCRE/IMD18 therapeutic antibody | Ubamatamab | | MUC16;CD3E | Bispecific Whole mAb | Detail |
GMP-Bios-ab-197 | Pre-Made Etevritamab biosimilar, Bispecific scFv, Anti-EGFR;CD3E Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;T3E/TCRE/IMD18 therapeutic antibody | Etevritamab | | EGFR;CD3E | Bispecific scFv | Detail |
GMP-Bios-ab-663 | Pre-Made Elranatamab biosimilar, Whole mAb, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody | Elranatamab | | TNFRSF17;CD3E | Bispecific Whole mAb | Detail |
GMP-Bios-ab-708 | Pre-Made Vepsitamab biosimilar, Whole mAb, Anti-MUC17;CD3E Antibody: Anti-MUC-17/MUC-3/MUC3;T3E/TCRE/IMD18 therapeutic antibody | Vepsitamab | | MUC17;CD3E | Bispecific scFv-scFv-scFc | Detail |
GMP-Bios-ab-446 | Pre-Made Plamotamab biosimilar, Bispecific Mixed mAb and scFv, Anti-MS4A1/CD20;CD3E Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7;T3E/TCRE/IMD18 therapeutic antibody | Plamotamab | | MS4A1/CD20;CD3E | Bispecific Mixed mAb and scFv | Detail |
GMP-Bios-ab-176 | Pre-Made Emerfetamab biosimilar, Bispecific scFv, Anti-CD33;CD3E Antibody: Anti-p67/SIGLEC3/SIGLEC-3;T3E/TCRE/IMD18 therapeutic antibody | Emerfetamab | | CD33;CD3E | Bispecific scFv | Detail |
GMP-Bios-ab-414 | Pre-Made Otelixizumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody | Otelixizumab | | CD3E | Whole mAb | Detail |
GMP-Bios-ab-562 | Pre-Made Teplizumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody | Teplizumab | | CD3E | Whole mAb | Detail |
GMP-Bios-ab-433 | Pre-Made Pavurutamab biosimilar, Bispecific scFv, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody | Pavurutamab | | TNFRSF17;CD3E | Bispecific scFv | Detail |
GMP-Bios-ab-709 | Pre-Made Voxalatamab biosimilar, Whole mAb, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibody | Voxalatamab | | FOLH1/GCPII;CD3E | Bispecific Whole mAb | Detail |
GMP-Bios-ab-570 | Pre-Made Tidutamab biosimilar, Bispecific Mixed mAb and scFv, Anti-SSTR2;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody | Tidutamab | | SSTR2;CD3E | Bispecific Mixed mAb and scFv | Detail |
GMP-Bios-ab-619 | Pre-Made Vibecotamab biosimilar, Bispecific Mixed mAb and scFv, Anti-IL3RA;CD3E Antibody: Anti-CD123/IL3RX/IL3RY/IL3RAY/hIL-3Ra;T3E/TCRE/IMD18 therapeutic antibody | Vibecotamab | | IL3RA;CD3E | Bispecific Mixed mAb and scFv | Detail |
GMP-Bios-ab-624 | Pre-Made Vixtimotamab biosimilar, Bispecific Homodimer (VK-VH-VL'-VH', Tandem diabody)), Anti-CD3E;CD33 Antibody: Anti-T3E/TCRE/IMD18;p67/SIGLEC3/SIGLEC-3 therapeutic antibody | Vixtimotamab | | CD3E;CD33 | Bispecific Homodimer (VK-VH-VL'-VH', Tandem diabody) | Detail |
GMP-Bios-ab-189 | Pre-Made Envafolimab biosimilar, Single Domain Variable Fragment;H, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PD-L1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1 therapeutic antibody | Epcoritamab | | CD3E;MS4A1/CD20 | Bispecific mAb | Detail |
GMP-Bios-ab-006 | Pre-Made Acapatamab biosimilar, Bispecific scFv, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibody | Acapatamab | | FOLH1/GCPII;CD3E | Bispecific scFv | Detail |
GMP-Bios-ab-074 | Pre-Made Blinatumomab biosimilar, Bispecific T-Cell Engager, Anti-CD19;CD3E Antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibody | Blinatumomab | | CD19;CD3E | Bispecific T-Cell Engager | Detail |
GMP-Bios-ab-650 | Pre-Made Zolimomab biosimilar, Whole mAb, Anti-CD5 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody | Zolimomab | | CD5 | Whole mAb | Detail |
GMP-Bios-ab-670 | Pre-Made Gresonitamab biosimilar, Whole mAb, Anti-CLDN18;CD3E Antibody: Anti-SFTA5/SFTPJ;T3E/TCRE/IMD18 therapeutic antibody | Gresonitamab | | CLDN18;CD3E | Bispecific scFv-scFv-scFc | Detail |
GMP-Bios-ab-421 | Pre-Made Pacanalotamab biosimilar, Bispecific scFv, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody | Pacanalotamab | | TNFRSF17;CD3E | Bispecific scFv | Detail |
GMP-Bios-ab-429 | Pre-Made Pasotuxizumab biosimilar, Bispecific scFv, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibody | Pasotuxizumab | | FOLH1/GCPII;CD3E | Bispecific scFv | Detail |
GMP-Bios-ab-130 | Pre-Made Dafsolimab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody | Dafsolimab | | CD3E | Whole mAb | Detail |
GMP-Bios-INN-772 | Pre-Made Catumaxomab Biosimilar, Bispecific, Anti-Cd3E; Epcam Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody | catumaxomab | | CD3E;EPCAM | Bispecific | Detail |
GMP-Bios-INN-921 | Pre-Made Muromonab-Cd3 3Iosimilar, Whole Mab, Anti-Cd3E Antibody: Anti-CD3epsilon/IMD18/T3E/TCRE therapeutic antibody | muromonab-CD3 | | CD3E | Whole? mAb | Detail |
GMP-Bios-ab-360 | Pre-Made Muromonab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody | Muromonab | | CD3E | Whole mAb | Detail |
GMP-Bios-ab-218 | Pre-Made Flotetuzumab biosimilar, Bispecific scFv with Crossover, Anti-IL3RA;CD3E Antibody: Anti-CD123/IL3RX/IL3RY/IL3RAY/hIL-3Ra;T3E/TCRE/IMD18 therapeutic antibody | Flotetuzumab | | IL3RA;CD3E | Bispecific scFv with Crossover | Detail |
GMP-Bios-ab-173 | Pre-Made Eluvixtamab biosimilar, Bispecific scFv, Anti-CD33;CD3E Antibody: Anti-p67/SIGLEC3/SIGLEC-3;T3E/TCRE/IMD18 therapeutic antibody | Eluvixtamab | | CD33;CD3E | Bispecific scFv | Detail |
GMP-Bios-ab-552 | Pre-Made Tarlatamab biosimilar, Bispecific scFv, Anti-DLL3;CD3E Antibody: Anti-SCDO1;T3E/TCRE/IMD18 therapeutic antibody | Tarlatamab | | DLL3;CD3E | Bispecific scFv | Detail |
GMP-Bios-ab-563 | Pre-Made Tepoditamab biosimilar, Bispecific mAb, Anti-CLEC12A/CD371;CD3E Antibody: Anti-CLL-1/CLL1/DCAL-2/MICL;T3E/TCRE/IMD18 therapeutic antibody | Tepoditamab | | CLEC12A/CD371;CD3E | Bispecific mAb | Detail |
GMP-Bios-ab-380 | Pre-Made Nivatrotamab biosimilar, Bispecific Mixed mAb and scFv, Anti-GD2;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody | Nivatrotamab | | GD2;CD3E | Bispecific Mixed mAb and scFv | Detail |
GMP-Bios-ab-018 | Pre-Made Alnuctamab biosimilar, Bispecific mAb with Domain Crossover, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody | Alnuctamab | | TNFRSF17;CD3E | Bispecific mAb with Domain Crossover | Detail |
GMP-Bios-ab-528 | Pre-Made Solitomab biosimilar, Bispecific scFv, Anti-EPCAM;CD3E Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1;T3E/TCRE/IMD18 therapeutic antibody | Solitomab | | EPCAM;CD3E | Bispecific scFv | Detail |
GMP-Bios-INN-845 | Pre-Made Ertumaxomab Biosimilar, Bispecific, Anti-Cd3E;Erbb2 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody | ertumaxomab | | CD3E;ERBB2 | Bispecific | Detail |
GMP-Bios-ab-557 | Pre-Made Teclistamab biosimilar, Bispecific mAb, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody | Teclistamab | | TNFRSF17;CD3E | Bispecific mAb | Detail |
GMP-Bios-ab-220 | Pre-Made Foralumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody | Foralumab | | CD3E | Whole mAb | Detail |
GMP-Bios-ab-555 | Pre-Made Tebentafusp biosimilar, scFv Fusion, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody | Tebentafusp | | CD3E | scFv Fusion | Detail |
GMP-Bios-ab-161 | Pre-Made Duvortuxizumab biosimilar, Bispecific scFv with Crossover, Anti-CD19;CD3E antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibody | Duvortuxizumab | | CD19;CD3E | Bispecific scFv with Crossover | Detail |
Click to check more INN-indexed antibody & protein biosimilar
Pre-made anti-CD3E inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-CD3E benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CD3E mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Antibody Name | Species | Format | Classified by tag | Detail |
Anti-CD3E monoclonal antibody | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | mab | FACS/Biofunctional Antibody, Therapeutics Target antibody | Detail |
Multi-species CD3E/ IMD18/ T3E VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine CD3E VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Products Name | Species | Expression Platform | Detail |
CD3E VLP (virus-like particle) | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | Mammalian cell | Products Developing |
Pre-made CD3E viral vector in GM Promise-ORFTM
About Promise-ORFTM:
Discover the largest collection of ORF/cDNA expression clones from different species, including human, mouse, rat, and more with GeneMedi's Promise-ORFTM. Our collection of ORFs expression clones come in verified mammalian or viral vectors lentivirus, AAV, and adenovirus) and our Promise-ORFTM viral-ready expression vectors make it easy for you to improve viral vector packaging efficiency or directly transfect mammalian cells, resulting in stronger and easier expression detection. Click to search your GOI
If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.